- Home
- IMUX vs SFWL Comparison
IMUX vs SFWL Comparison
Compare IMUX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | SFWL |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 78.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | IMUX | SFWL |
|---|---|---|
| Price | $0.58 | $1.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 90.6K |
| Earning Date | 11-13-2025 | 08-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.68 |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $540,461,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.12 |
| Revenue Growth | N/A | ★ 21.10 |
| 52 Week Low | $0.56 | $0.56 |
| 52 Week High | $1.39 | $1.29 |
Technical Indicators
Market Signals| Indicator | IMUX | SFWL |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 55.51 |
| Support Level | $0.58 | $0.56 |
| Resistance Level | $0.70 | $1.18 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.72 | 70.76 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.